<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00304668</url>
  </required_header>
  <id_info>
    <org_study_id>IPM005A</org_study_id>
    <nct_id>NCT00304668</nct_id>
  </id_info>
  <brief_title>A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in South Africa</brief_title>
  <official_title>A Phase I/II Single-Centre Double-Blinded Randomized Study of the Safety and Tolerability of TMC120 Vaginal Microbicide Gel (TMC120 Gel-002) vs. HEC-Based Universal Placebo Gel in Healthy HIV-Negative Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Partnership for Microbicides, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Partnership for Microbicides, Inc.</source>
  <brief_summary>
    <textblock>
      Approximately 42 HIV-negative women, aged &gt;18 and &lt; 50, will be enrolled in this study. Each&#xD;
      volunteer will have a 2:1 chance of receiving Dapivirine Gel-002 versus placebo. The&#xD;
      volunteers will receive investigational product for a total of 42 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local and systemic safety and tolerability.</measure>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapivirine (TMC120) vaginal gel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-negative&#xD;
&#xD;
          -  Willing to participate and sign an informed consent form&#xD;
&#xD;
          -  Willing to be tested for HIV, use an experimental vaginal gel, and to be randomized to&#xD;
             a study group that includes the possibility of being assigned to a placebo group.&#xD;
&#xD;
          -  Willing to use two forms of contraception during the study&#xD;
&#xD;
          -  Willing to undergo pelvic examinations with colposcopy and photographic documentation&#xD;
             according to the protocol throughout the study.&#xD;
&#xD;
          -  Have a regular menstrual cycle defined as having a minimum of 21 days and a maximum of&#xD;
             36 days between menses&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently pregnant or breast-feeding&#xD;
&#xD;
          -  Clinically detectable genital abnormality on the vulva, vaginal walls or cervix&#xD;
&#xD;
          -  Laboratory confirmed gonorrhea, chlamydia, trichomonas, syphilis, or vaginal&#xD;
             candidiasis or clinically diagnosed GUD or active HSV-2 lesion&#xD;
&#xD;
          -  Breakthrough bleeding or gynecologic surgery within 60 days prior to randomization&#xD;
&#xD;
          -  Symptomatic bacterial vaginosis at Screening and unwilling to undergo treatment.&#xD;
&#xD;
          -  Women who require treatment for tuberculosis (TB) within 21 days prior to&#xD;
             randomization.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zeda Rosenberg, ScD</last_name>
    <role>Study Director</role>
    <affiliation>IPM</affiliation>
  </overall_official>
  <removed_countries>
    <country>South Africa</country>
  </removed_countries>
  <verification_date>May 2006</verification_date>
  <study_first_submitted>March 17, 2006</study_first_submitted>
  <study_first_submitted_qc>March 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2006</study_first_posted>
  <last_update_submitted>December 8, 2015</last_update_submitted>
  <last_update_submitted_qc>December 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2015</last_update_posted>
  <keyword>HIV-1</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapivirine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

